Group 1 - In 2023, 25.5% of the 55 new listings in Hong Kong are from the healthcare sector, with 14 companies in this industry [1] - The head of Asia Pacific Healthcare Investment Banking at Citigroup noted a significant shift in biotech financing preferences, with companies now favoring the US and Asia Pacific markets over Europe [3] - The trend of companies moving their listings from Europe to the US is increasing, with major pharmaceutical firms considering this shift [3] Group 2 - Hong Kong's biotech ETF has risen by 30% this year, while the US market has shown no performance, indicating a strong local market [4] - The Hang Seng Index has performed well, particularly in the healthcare sector, with biotech stocks increasing by 80% and pharmaceutical companies by 60% [4] - International funds are participating in Hong Kong's biotech sector, as evidenced by recent fundraising activities, indicating a broader interest beyond just mainland Chinese capital [4]